Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer
Executive Summary
Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.
You may also be interested in...
Epizyme Emerges From Stealth Mode
Tiny start-up aims to be a dominant player in the unfolding field of epigenetics.
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals